title: Midodrine and cool dialysate are effective therapies for symptomatic intradialytic hypotension.
abstract: Intradialytic hypotension (IDH) is a morbid complication of hemodialysis (HD). Both midodrine, an oral selective alpha1 agonist, and cool dialysate have been reported as useful therapies for this problem. We performed this prospective crossover study to compare the efficacy of these two therapies, alone and in combination, for IDH. The study consisted of a control phase and three treatment phases: midodrine phase (10 mg oral dose pre-HD), cool dialysate phase (35.5 degrees C), and combination therapy phase (midodrine, 10 mg, and dialysate temperature, 35.5 degrees C). Each phase consisted of nine consecutive HD treatments. Eleven patients (six men, five women; mean age, 67.5 years) with known symptomatic IDH were studied. This cohort was followed up in terms of blood pressure measurements (pre-HD blood pressure, lowest intradialytic blood pressure, post-HD blood pressure), weights, laboratory values, and interventions for IDH. The lowest intradialytic blood pressures were significantly better with midodrine and cool dialysate compared with the control phase (systolic blood pressure [SBP], 103.9 +/- 4.1 [mean +/- standard error of the mean] and 102.6 +/- 2.9 v 90.6 +/- 2.5 mm Hg, respectively; P < 0.001), as were the post-HD blood pressures (SBP, 116.9 +/- 4.0 and 118.2 +/- 3.5 v 109.0 +/- 2.1 mm Hg; P < 0.01). In addition, the lowest intradialytic blood pressures were significantly better with the combination phase compared with the control phase (SBP, 103.7 +/- 4.2 v 90.6 +/- 2.5 mm Hg; P < 0.001), as were the post-HD blood pressures (SBP, 122.1 +/- 4.6 v 109.0 +/- 2.1 mm Hg; P < 0.01). There was a significant reduction in the number of nursing interventions performed and volume of saline infused for IDH with midodrine and cool dialysate compared with control. There was a trend toward amelioration of hypotensive symptoms with both therapies. Laboratory values, including Kt/V, did not change significantly with either midodrine or cool dialysate. This prospective study shows that both midodrine and cool dialysate are effective therapies for symptomatic IDH. There does not seem to be additional benefit when these two therapies are used in combination.
authors.affiliation: Department of Internal Medicine, Gambro Dialysis Center at Yale University, New Haven, CT, USA.
authors.forename: D N
authors.initials: DN
authors.lastname: Cruz
authors.forename: R L
authors.initials: RL
authors.lastname: Mahnensmith
authors.forename: H M
authors.initials: HM
authors.lastname: Brickel
authors.forename: M A
authors.initials: MA
authors.lastname: Perazella
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001794:Blood Pressure; D003080:Cold Temperature; D003131:Combined Modality Therapy; D018592:Cross-Over Studies; D005260:Female; D015312:Hemodialysis Solutions; D006801:Humans; D007022:Hypotension / Q000517:prevention & control*; D007676:Kidney Failure, Chronic / Q000628:therapy; D008297:Male; D008875:Middle Aged; D008879:Midodrine / Q000627:therapeutic use*; D011446:Prospective Studies; D006435:Renal Dialysis / Q000009:adverse effects; D014662:Vasoconstrictor Agents / Q000627:therapeutic use*
chemical_list: D015312:Hemodialysis Solutions; D014662:Vasoconstrictor Agents; D008879:Midodrine